2nd ACMA/DGE Medical Affairs
& Rare Disease - West Coast

Cross Functional Collaboration in Rare Disease:
Breaking Down Silos to Identify Solutions

May 13-15, 2020

San Diego, CA

Event Overview

The Accreditation Council for Medical Affairs and Dynamic Global Events are excited to announce the 2nd Annual Medical Affairs in Rare Diseases Forum on the west coast. This is a CE/CME- accredited conference for life sciences professionals in rare and ultra-rare diseases.
 
Join with thought leaders and decision makers to become a strong and collaborative medical affairs partner who will work collaboratively to drive better medical strategies affecting therapy research (orphan drugs, gene therapies, biosimilars/biologics, T-Cell), pharmacovigilance, clinical trials, HEOR, launches, medical communications, domestic/international brand plans, drug/patient safety . This forum will provide actionable insights into best practices for building and leading high-performing multi-stakeholder teams across functions, geographies, therapeutic areas and organizations to solve problems and identify solutions in rare disease.

Wyndham Bayside San Diego

Image

1355 N Harbor Dr.
San Diego, CA 92101
(619) 232-3861

Hotel Website

About the Chairperson

Image

Dr. Matthew T. Roe has been a faculty member at Duke University School of Medine and the Duke Clinical Research Institute (DCRI) since 1999. As a senior investigator at the DCRI, he has been the principal investigator for numerous phase II-IV cardiovascular clinical trials and is currently a co-principal investigator for the ADAPTABLE trial—the first large-scale pragmatic trials being conducted in the PCORnet network. He has also served in leadership roles for several observational registries focusing upon the treatment and outcomes of patients with cardiovascular disease and has served as the Director of the DCRI Clinical Research Fellowship since 2010.

Featured Speakers

Image

Craig Lipset

Head of Clinical Innovation
Pfizer

Image

Jeff Kingsley

Chief Executive Officer
IACT Health 

Image

Dawn Anderson

Managing Director, Life Sciences Strategy and Operations, R&D Practice
Deloitte

Image

Ross Friedberg

General Counsel & Chief Privacy Officer
Doctor on Demand

Top Reasons to Attend

  1. Discover the latest therapeutic advances medical affairs teams are using to achieve success in rare disease patient outcomes
  2. Optimize your medical affairs teams’ abilities to understand patient needs and create patient-centric real world evidence
  3. Understand the regulatory pathway and nuances for the orphan drug approval process and the value of natural history studies in gene therapy
  4. Learn best practices for building and leading high-performing multi-stakeholder teams across functions, geographies, therapeutic areas and organizations to solve problems and identify solutions in rare disease
  5. Earn CME/CE credits

Attendee Profile

This Conference is Designed for Life Science Professionals responsible for:

  • Rare Disease
  • Orphan Drugs
  • Biosimilars/Biologics
  • Gene Therapy
  • T-Cell Studies
  • Medical Affairs
  • Clinical Affairs
  • Quality Assurance
  • Pharmacovigilance
  • Drug/Patient Safety
  • Regulatory Affairs
  • Compliance
  • Product Development
  • Product Launch
  • Health Economics and Outcomes Research/HEOR
  • Reimbursements
  • Medical Messaging
  • Marketing
  • Clinical Research Organizations (CROs)
  • eClinical Technologies
  • Data Management/Integration
  • Patient Engagement
  • Patient Advocacy
  • Medical Science Liaisons (MSLs)
  • KOL/Thought Leader Relations/Engagement
  • Cross Functional Team Management
  • Strategic Planning
  • Medical Publication/Digital Communication Planning
  • University/Medical School Rare Disease Research

Wednesday

May 13th, 2020 | Day 1

8:00 AM - 9:00 AM

Registration & Continental Breakfast

9:00 AM - 9:15 AM

Conference Opening Remarks

9:15 AM - 10:00 AM

Gene Therapy Value Propositions

Oscar Segurado, MD, PhD - Chief Medical Officer
ASC Therapeutics

10:00 AM - 10:45 AM

Creating a Best-in-Class Safety/PV Department – Key Differences between Big Pharma and Small Biotech in Rare Disease

Judy T. Hsiung, DPM - Vice President, Safety and Pharmacovigilance
ARENA PHARMACEUTICALS

10:45 AM - 11:00 AM

Morning Networking Break

11:00 AM - 12:00 PM

PANEL: Access to Orphan Drugs – Fast Tracking, Early Access and Expanded Access

12:00 PM - 1:00 PM

Networking Lunch

1:00 PM - 1:45 PM

Collaborating Around Rare Disease

Jon Kaskey - Regional Vice President, Business Partnerships
WITHIN3

1:45 PM - 2:45 PM

Patient Diversity – Increasing Awareness Among and Participants from the Latino, African American and Native American Communities in Rare Disease Clinical Trials

GSK US

2:45 PM - 3:00 PM

Afternoon Networking Break

3:00 PM - 4:00 PM

Critical Considerations in the Transition to Automated Systems Implementation

Israel Gutierrez - Vice President, Pharmacovigilance & Drug Safety
GERON CORPORATION

4:00 PM - 4:45 PM

Digital Tools for the Benefit-Risk Optimization of Medicines

Michael Forstner-Dambenois - Senior Vice President - Head of Pharmacoepidemiology & Risk Management
PRIMEVIGILANCE LTD.

4:45 PM - 5:00 PM

Day 1 Closing Remarks

Thursday

May 14th, 2020 | Day 2

8:00 AM - 9:00 AM

Registration & Continental Breakfast

9:00 AM - 9:15 AM

Re-cap of Day 1 & Day 2 Opening Remarks

9:15 AM - 10:00 AM

Determining the Value of Rare Disease Therapies

10:00 AM - 10:45 AM

Off-Label Use of Rare Disease Drugs

10:45 AM - 11:00 AM

Morning Networking Break

11:00 AM - 12:00 PM

PANEL – Drug Pipelines for Bi-specific Antibodies, T-cell, Neo Personalized Cancer Immunotherapy, Rare Neuromuscular Diseases

12:00 PM - 1:00 PM

Networking Lunch

1:00 PM - 1:45 PM

Session Topic TBD

Robert Consalvo - Sales Director
H1 INSIGHTS

1:45 PM - 2:30 PM

Translational Medicine in Rare Disease

2:30 PM - 2:45 PM

Afternoon Networking Break

2:45 PM - 3:45 PM

Patient Centricity and Including the Patient Voice in Clinical Trials

3:45 PM - 4:30 PM

Knowledge Transfer in Rare Disease

4:30 PM - 4:45 PM

Day 2 Closing Remarks

Friday

May 15th, 2020 | Workshop

8:00 AM - 9:00 AM

Registration & Continental Breakfast

9:00 AM - 9:15 AM

Workshop Opening Remarks

9:15 AM - 10:45 AM

Best Practices for Building High-performing Multi-stakeholder Teams Across Science, Business and Non-Profits to Solve Problems and Identify Solutions in Rare Disease

10:45 AM - 11:00 AM

Networking Break

11:00 AM - 12:30 PM

Best Practices for Leading Diverse Projects Across Functions, Geographies, Therapeutic Areas, and Organizations to Achieve Clinical Development, Product Launch Goals, Drug Safety and Favorable Patient Outcomes

12:30 PM - 1:00 PM

Workshop Closing Remarks

FEATURED SPEAKERS

Image

Ronald Walls

The CSPC Pharmaceutical Group

US Head of Operations, & Business Development, Vice President Clinical Development Medical Affairs

Image

Dakota Fisher-Vance

Young Adult Cancer Connection

Founder (Also Patient Advocacy Manager, Horizon Therapeutics)

Image

Dan Donovan

rare Life SOLUTIONS

Founder

CONFERENCE REGISTRATION


ATTENDEE + WORKSHOP PRICING

* SUPER EARLY BIRD *

Available for

$2,196

EARLY BIRD

Before 3/27/20

$2,396

STANDARD

Register Before Event

$2,596

ON-SITE

Register at Event

$2,796

ATTENDEE PRICING

* SUPER EARLY BIRD *

Available for

$1,596

EARLY BIRD

Before 3/27/20

$1,796

STANDARD

Register Before Event

$1,996

ON-SITE

Register at Event

$2,196

Register 2 Attendees, Get 1 Complimentary Registration*!

Interested in sending groups of 7 or more? Contact us directly for pricing.

EVENT SPONSORS



SPONSOR THIS EVENT

Contact Amy Chapman at (561) 571-7687
or achapman@dgeconfs.com


MEDIA PARTNERS

Image

PREMIER MEDIA PARTNER


Why Become Board Certified in Medical Affairs?

Image

Certification is becoming an important factor in the healthcare industry in general. A survey of over 1000 key opinion leaders (KOLs) found that over 90% preferred medical affairs professionals who had a Board Certified Medical Affairs Specialist (BCMAS) designation.

Several pharmaceutical companies also look at certification as a way to assess whether an individual possesses the skills and knowledge required for successful performance in a medical affairs role. Why are companies looking for this assurance? They want to hire the best of the best. By becoming board certified in your field of expertise, and by maintaining BCMAS, you are saying that you:

  • Have met standards that have been established and verified by a credible, accrediting body.
  • Are dedicated to maintaining quality of excellence in your profession.

These are powerful statements that speak volumes about you as a professional and the company or organization you represent. Board certification demonstrates that you are committed to your profession and that you want to continue to learn and grow.
Studies have shown that individuals who are certified in their field have higher salaries and better promotion opportunities.

Top 5 Reasons Why You Should Certify with the ACMA:

  1. Accredited: The ACMA is recognized nationally & internationally as a true mark of quality and excellence in the pharmaceutical industry for medical affairs professionals. The ACMA is accredited by the International Association for Continuing Education & Training (ANSI/IACET) which is the gold standard for certification & training around the world. Our program is administered and analyzed using the highest industry standards and state-of-the-art psychometric methodologies.
  2. Distinguish Yourself: Because ACMA offers multiple but related certificates, you can more readily become certified in more than one specialty, making you more valuable and marketable in the field.
  3. Go International: ACMA certification is widely accepted throughout the US as well as internationally with 25% of BCMAS graduates coming from outside the US.
  4. Expand Your Network: Once certified by ACMA you automatically become a member of the 75,000+ strong ACMA organization and gain access to a multitude of benefits, including discounts on continuing education, leadership opportunities, and access to a mentor to help you get ahead.
  5. Be on the cutting edge: ACMA board certification in medical affairs is the future of the life sciences and pharmaceutical industry.

Interested in BCMAS?

By attending any DGE/ACMA conference, receive 10% off of BCMAS registration.

Already BCMAS Certified? Receive 10% off your conference registration!